ondansetron has been researched along with epirubicin in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (60.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 3 (15.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dicato, MA | 1 |
| Adler, M; Christmann, D; Fenzl, E; Marschner, NW; Nagel, GA; Upadhyaya, B | 1 |
| Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M | 1 |
| Adler, M; Albrecht, U; Jaenicke, F; Marschner, NW; Nagel, GA | 1 |
| Behnam Motlagh, P; Grankvist, K; Henriksson, R | 1 |
| Adenis, A; Bonneterre, J; Hebbar, M; Hecquet, B; Lecomte, S; Pion, JM; Vanlemmens, L | 1 |
| Barrenetxea, G; Centeno, MM; de la Rica, M; Rodríguez-Escudero, FJ; Romero, H; Schneider, J | 1 |
| Ionta, MT; Massidda, B | 1 |
| du Bois, A; Holy, R; Kriesinger-Schröder, H; Vach, W | 1 |
| Cannata, G; Gebbia, N; Gebbia, V; Testa, A | 1 |
| Fukui, H; Hoshino, K; Ikeda, M; Kawaguchi, H; Kimura, O; Ono, K | 1 |
| Abe, T; Hashimoto, Y; Kojima, A; Mori, M; Nagamine, T; Sohara, N; Takagi, H; Takahashi, H | 1 |
| Raina, V; Sharma, A | 1 |
| Bohidar, N; Eisenberg, PD; Gabriel, M; Gralla, RJ; Grunberg, SM; Herrstedt, J; Hesketh, PJ; Horgan, KJ; Hustad, CM; Klinger, G; Muss, HB; Raftopoulos, H; Rodgers, A; Skobieranda, F; Warr, DG | 1 |
| Bani, MR; Beckmann, MW; Engel, J; Fasching, PA; Kollmannsberger, B; Kreis, H; Lausen, B; Lux, MP; Niesler, B; Strick, R; Strissel, PL; Weihbrecht, S | 1 |
| de Camargo, B; del Giglio, A; Lajolo, PP | 1 |
| Eksborg, S; Lönnqvist, PA; Öbrink, E; Oddby-Muhrbeck, E; Rotstein, S | 1 |
1 review(s) available for ondansetron and epirubicin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
9 trial(s) available for ondansetron and epirubicin
| Article | Year |
|---|---|
Oral treatment with ondansetron in an outpatient setting.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Humans; Imidazoles; Male; Middle Aged; Nausea; Ondansetron; Serotonin Antagonists; Vomiting | 1991 |
Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Imidazoles; Metoclopramide; Middle Aged; Nausea; Ondansetron; Vomiting | 1991 |
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Epirubicin; Fluorouracil; Humans; Imidazoles; Infusions, Intravenous; Metoclopramide; Middle Aged; Nausea; Ondansetron; Randomized Controlled Trials as Topic; Time Factors; Vomiting | 1990 |
[Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Imidazoles; Metoclopramide; Neoplasm Metastasis; Ondansetron; Serotonin Antagonists; Vomiting | 1990 |
Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Methotrexate; Metoclopramide; Ondansetron; Patient Satisfaction; Quality of Life; Surveys and Questionnaires; Vomiting | 1996 |
Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Granisetron; Granulocyte Colony-Stimulating Factor; Humans; Indoles; Injections, Intravenous; Methotrexate; Middle Aged; Ondansetron; Serotonin Antagonists; Tropisetron; Vomiting | 1996 |
5-Hydroxyindoleacetic acid excretion following combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil plus ondansetron compared to ondansetron alone.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Hydroxyindoleacetic Acid; Incidence; Middle Aged; Ondansetron; Selective Serotonin Reuptake Inhibitors; Vomiting | 1996 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Morpholines; Nausea; Ondansetron; Vomiting | 2005 |
Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost Savings; Dexamethasone; Double-Blind Method; Doxorubicin; Epirubicin; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Prognosis; Prospective Studies; Ranitidine; Treatment Outcome; Vomiting | 2009 |
10 other study(ies) available for ondansetron and epirubicin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro.
Topics: Animals; Antibiotics, Antineoplastic; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bleomycin; Cells, Cultured; Cisplatin; Cricetinae; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Interactions; Epirubicin; Estramustine; Fibroblasts; Granisetron; Humans; Lung Neoplasms; Ondansetron; Serotonin Antagonists; Tumor Cells, Cultured | 1995 |
[Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Male; Nausea; Ondansetron; Tablets; Treatment Outcome; Vomiting | 1995 |
Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Epirubicin; Female; Humans; Lung Neoplasms; Male; Metoclopramide; Middle Aged; Nausea; Ondansetron; Ovarian Neoplasms; Pilot Projects; Prednisolone; Uterine Neoplasms; Vinblastine; Vinorelbine; Vomiting | 1996 |
[Usefulness of continuous venous daily chemotherapy of 5-fluorouracil and low-dose cisplatin for patients undergoing noncurative surgery].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Ondansetron; Prognosis; Remission Induction; Vomiting | 1997 |
Nausea and vomiting induced by arterial chemo-embolization in patients with hepatocellular carcinoma and the antiemetic effect of ondansetron hydrochloride.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Eating; Epirubicin; Female; Follow-Up Studies; Humans; Incidence; Infusions, Intra-Arterial; Injections, Intra-Arterial; Iodized Oil; Liver Neoplasms; Male; Maleic Anhydrides; Middle Aged; Mitomycin; Nausea; Ondansetron; Polystyrenes; Quality of Life; Vomiting; Zinostatin | 1999 |
Generalised seizures following ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Ondansetron; Seizures | 2001 |
Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Epirubicin; Female; Genotype; Humans; Nausea; Ondansetron; Polymorphism, Single Nucleotide; Receptors, Serotonin, 5-HT3; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Vomiting | 2008 |
Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease Resistance; Droperidol; Epirubicin; Female; Fluorouracil; Granisetron; Humans; Mastectomy; Methotrexate; Metoclopramide; Middle Aged; Models, Biological; Narcotics; Nausea; Ondansetron; Postoperative Nausea and Vomiting; Prospective Studies; Risk Factors; Vomiting | 2013 |